Finance

Could a nation bolt Bitcoin into its financial defenses? A bold legislative proposal would create a government-run crypto reserve, locked for 20 years and dedicated solely to paying down debt. With cold storage, audits, and tight governance, this plan tests how far digital assets can reshape national finance.

Football season just got a new layer for traders. Robinhood is expanding its prediction markets to include professional and college football, with a phased rollout timed to kickoff and weekly additions on the way. A bold move in its quest to be an all-in-one trading platform.

Ethereum appears poised to lead the next crypto cycle as liquidity and institutional demand tilt the odds in ETH’s favor. Solana isn’t left out, but the expectation is for ETH to outperform on a percentage basis. Three pillars—positioning, flows, and trajectory—frame the case for a potential ETH-driven rally as the cycle unfolds.

– Ethereum rides a fresh rally on ETF demand and sturdy on-chain signals, but early profit-taking and looming macro data could spark a pause. Will the momentum hold? – ETH has extended gains on institutional inflows, yet signs of near-term cooling are emerging ahead of key inflation and policy events. – A powerful ETH rally…

Bitcoin sits just above a key 112,500 support as markets brace for Powell’s Jackson Hole remarks. With hedging and options activity on the move, a dovish read could spark a short-term relief rally, while hawkish signals might keep the downside pressure in play.

AI-driven momentum is driving tech stocks to fresh highs in 2025. A quick look at the forces behind the rally—from chipmakers to cloud leaders—and what it could mean for a long-term growth strategy in tech.

An influential analyst boosts Nio’s target on optimism around restructuring and the new Onvo brand. While near-term hurdles remain, the setup hints at improving margins and a clearer path to profitability as Onvo gains traction.

Powell’s Jackson Hole appearance could signal the Fed’s next move as a global policy audience watches closely. With labor markets shifting and inflation in focus, the path for rates in the coming months remains under debate—while an international perspective from Lagarde adds to the tension. A hints-at-answers moment that could move markets.

Snowflake sits in the mid-190s as analysts send mixed signals and insiders trim stakes. Revenue growth is clear, but profitability remains a hurdle, shaping a cautious near-term backdrop ahead of the next results.

Palantir’s latest earnings rally has investors eyeing a potential turn toward durable, profitable growth. With government and enterprise demand fueling revenue momentum, the next leg will hinge on margins and cash flow translating into sustained profitability.

A Palantir trade that didn’t go as planned shows how momentum can outrun fundamentals in the short run. Explore the risk-management lessons and what this means for navigating volatile tech names when sentiment shifts.

SUI faces a tug-of-war between fresh institutional traction and softer price action. A Swiss bank partnership and an ETF filing signal ambition, but momentum remains mixed as traders eye critical levels. The coming days could reveal whether the institution-led narrative can translate into a sustained move or keep markets range-bound.

Novo Nordisk has pulled back even as its diabetes and obesity franchises stay durable. A value‑oriented, fundamentals‑first view weighs long‑term cash flow and credible competitive advantages against a complex growth path, spotlighting a patient-entry thesis for investors who value quality earnings over headlines.

Big investors are upping their Samsara exposure as Invesco boosts its stake while insiders reposition shares. The company posted revenue growth and beat earnings expectations, yet profitability remains a hurdle with negative margins and an uncertain outlook. Analysts are broadly mixed but increasingly constructive, with several price targets nudging higher. Ongoing insider activity and expanding…

Tonix’s fate could hinge on a FDA decision today for TNX-102 SL, a novel non-opioid, sublingual treatment for fibromyalgia. If approved, it could mark a first-in-class approach and reshape the company’s near-term trajectory. The ruling has potential implications for patients and the broader treatment landscape.

Salesforce faces near-term execution questions even as its AI ambitions push ahead, after a price-target trim with the Buy rating kept. With Dreamforce 2025 on the horizon, all eyes will be on AI progress, pricing moves, and the data strategy.

Mortgage rates edged lower again this week, giving buyers a glimmer of relief while refinancing activity picks up. Yet with inflation stubborn and policy signals evolving, the road for rates—and real affordability—remains uncertain.

Taxpayers keep an eye on possible 2025 relief as debates over a fourth stimulus check, tariff rebates, and inflation relief unfold. With state programs already in motion and federal refund guidance in flux, this snapshot highlights what could be next and how to stay informed.

UnitedHealth Group has endured a tough year, with shares sliding on Medicare Advantage costs and regulatory headwinds. Yet its steady dividend and a path toward brighter earnings in 2026 keep it on investors’ radar despite near-term headwinds. With mixed analyst views and policy shifts in play, the balance of risk and reward remains a focal…